This study aims to test if a new drug combination, *acasunlimab* and *pembrolizumab*, is better than the typical chemo drug, *docetaxel*, for people with a type of lung cancer called *non-small cell lung cancer* (NSCLC). NSCLC is a cancer that has spread and has a specific protein, PD-L1, which might affect how well treatments work. Participants must have tried certain treatments before, like a *PD-1/PD-L1 inhibitor* and a *platinum-based chemotherapy*.
Participants will get either the new drug combo or docetaxel. The study may last up to 5 years, including treatment and follow-ups. Trial length varies for each person.
- Time Commitment: Up to 5 years, including a 3-month pre-screening, treatment up to 2 years, and follow-ups.
- Visits and Treatment: Receive new drugs every 6 weeks or docetaxel every 3 weeks.
- Risks and Benefits: New treatment's effectiveness and safety will be compared to standard treatment.
How understandable was the trial content above?
Hard to understand
Easy to understand